Shikimic Acid(CAS 138 59 0) Market Size, Share, Growth, and Industry Analysis, By Type (Shikimic Acid (98%), Shikimic Acid (99%)), By Application (Medicine and Veterinary Drugs, Cosmetic and Personal Care, Others), Regional Insights and Forecast to 2035

Shikimic Acid(CAS 138 59 0) Market Overview

The global Shikimic Acid(CAS 138 59 0) Market size estimated at USD 44.71 million in 2026 and is projected to reach USD 69.62 million by 2035, growing at a CAGR of 5.04% from 2026 to 2035.

The Shikimic Acid(CAS 138 59 0) Market is expanding as pharmaceutical, veterinary, cosmetic, and specialty chemical manufacturers increase demand for bio-based intermediates with functional applications. Shikimic acid is an important biochemical compound used as an intermediate in pharmaceutical synthesis, particularly in antiviral drug production, while also gaining attention in cosmetic and personal-care formulations because of its bioactive properties. The market includes 2 supplied product categories, Shikimic Acid (98%) and Shikimic Acid (99%), with Shikimic Acid (99%) estimated to lead demand with approximately 57% share in 2026 due to higher purity requirements in pharmaceutical and advanced applications. The market serves 3 supplied applications: Medicine and Veterinary Drugs, Cosmetic and Personal Care, and Others. Medicine and Veterinary Drugs are estimated to represent approximately 62% of demand because shikimic acid remains strategically important as a pharmaceutical intermediate and is widely associated with antiviral drug supply chains.

The United States represents an important Shikimic Acid(CAS 138 59 0) Market due to advanced pharmaceutical research, biotechnology capabilities, specialty chemical demand, and growing interest in plant-derived bioactive compounds. Pharmaceutical manufacturers continue exploring reliable sources of important intermediates as healthcare systems require consistent supply of active pharmaceutical ingredients and related compounds. Shikimic acid is commercially significant because it serves as a precursor in the synthesis of oseltamivir and other biochemical applications. The U.S. market is also supported by demand from cosmetic and personal-care companies seeking naturally derived ingredients for premium formulations. Companies are focusing on improving extraction efficiency, purification technologies, production consistency, and supply-chain reliability. Increasing interest in sustainable chemistry and bio-based ingredients is encouraging manufacturers to evaluate advanced processing methods that improve quality while maintaining competitive production economics.

Key Findings

• Market Driver: Pharmaceutical demand remains the key growth factor, with Medicine and Veterinary Drugs applications estimated to represent approximately 62% of market demand due to antiviral and pharmaceutical intermediate usage.
• Major Market Restraint: Limited raw-material availability and extraction complexity can restrict supply stability because shikimic acid production requires controlled sourcing, purification, and quality-management processes.
• Emerging Trends: High-purity ingredient demand is increasing, with Shikimic Acid (99%) estimated to account for approximately 57% of product demand as pharmaceutical applications require stricter quality standards.
• Regional Leadership: Asia-Pacific is estimated to lead with approximately 46% market share in 2026, supported by botanical sourcing capabilities, pharmaceutical manufacturing, and established specialty chemical production networks.
• Competitive Landscape: Competition among the 9 supplied companies focuses on extraction technology, purification quality, production capacity, pharmaceutical-grade supply, and expansion into cosmetic ingredient markets.
• Market Segmentation: Shikimic Acid (99%) leads product demand with approximately 57% share, while Medicine and Veterinary Drugs dominate applications with nearly 62% share due to pharmaceutical intermediate requirements.
• Recent Development: Manufacturers increased investment during 2025-2026 in purification technologies and bio-based production methods to improve consistency, scalability, and quality of shikimic acid supplies.

Latest Trends

Increasing pharmaceutical demand is one of the strongest trends shaping the Shikimic Acid(CAS 138 59 0) Market as manufacturers seek reliable sources of high-quality intermediates for drug synthesis. Shikimic acid is widely recognized as a key biochemical precursor associated with oseltamivir production and continues to maintain importance within pharmaceutical supply chains. The demand for higher-purity grades is increasing as pharmaceutical manufacturers require consistent chemical characteristics and improved quality control. Shikimic Acid (99%) is estimated to represent approximately 57% of product demand because advanced pharmaceutical applications often require higher purity specifications. Producers are improving extraction methods, purification systems, and analytical testing procedures to achieve better consistency. Biotechnology-assisted production approaches are also gaining attention as companies seek alternatives to traditional botanical extraction methods. These developments are helping suppliers improve production reliability while addressing increasing demand from pharmaceutical and specialty-chemical industries.

Another important trend is the expansion of shikimic acid applications beyond pharmaceutical intermediates into cosmetic and personal-care formulations. Consumers are increasingly interested in naturally derived and bio-based ingredients, encouraging cosmetic manufacturers to explore plant-origin compounds with functional properties. Cosmetic and Personal Care applications are estimated to represent approximately 25% of market demand as brands develop premium formulations incorporating specialized natural ingredients. Manufacturers are focusing on improving ingredient purity, stability, and formulation compatibility to support broader adoption. Sustainability is also influencing product development as companies seek efficient extraction processes and responsible sourcing strategies. The combination of pharmaceutical importance, cosmetic innovation, and increasing interest in bio-based compounds is expected to support continued market expansion through 2035.

Market Dynamics

Driver

"Pharmaceutical applications are strengthening shikimic acid demand."

The primary driver for the Shikimic Acid(CAS 138 59 0) Market is increasing demand from pharmaceutical applications, particularly as the compound remains an important intermediate in antiviral drug synthesis. Medicine and Veterinary Drugs represent approximately 62% of market demand, making pharmaceutical usage the largest commercial segment. Shikimic acid's biochemical importance and role in pharmaceutical supply chains continue supporting demand among manufacturers requiring reliable intermediate materials. Growth in healthcare research, pharmaceutical production, and specialty medicine development is encouraging companies to maintain stable supply networks. Manufacturers are investing in improved purification technologies, quality-control systems, and production optimization to meet pharmaceutical-grade requirements. The increasing importance of bio-based compounds in healthcare and specialty chemical applications is expected to remain a major growth factor through 2035.

Restraint

"Production complexity limits supply flexibility."

A significant restraint for the Shikimic Acid(CAS 138 59 0) Market is the complexity associated with sourcing, extraction, purification, and quality control. Shikimic acid production traditionally depends on botanical sources and requires careful processing to achieve pharmaceutical-grade purity. Variations in raw-material availability, seasonal factors, extraction efficiency, and purification requirements can influence supply consistency. Higher-purity products require additional processing steps, increasing production costs and technical requirements. Manufacturers must maintain strict quality standards because pharmaceutical applications require reliable chemical characteristics. These challenges can limit rapid capacity expansion and create supply-chain pressure during periods of increased demand. Companies are therefore exploring improved production methods, alternative sourcing strategies, and advanced purification technologies to enhance scalability and reduce operational challenges.

Opportunity

"Bio-based ingredient demand creates new market opportunities."

The growing preference for natural and bio-derived ingredients creates significant opportunities for shikimic acid manufacturers. Cosmetic and Personal Care applications represent approximately 25% of demand and provide expansion potential as brands increasingly incorporate plant-derived compounds into premium formulations. Shikimic acid's positioning as a naturally occurring biochemical compound creates opportunities in skincare, wellness, and specialty ingredient markets. Companies can benefit by developing higher-purity grades, improving formulation compatibility, and expanding distribution across cosmetic and specialty chemical industries. Asia-Pacific provides additional opportunities because of its botanical resources, pharmaceutical manufacturing capabilities, and established ingredient supply chains. Manufacturers investing in sustainable extraction, biotechnology-assisted production, and customized ingredient solutions are positioned to capture emerging demand.

Challenge

"Maintaining consistent quality across production sources remains challenging."

The major challenge for the Shikimic Acid(CAS 138 59 0) Market is maintaining consistent product quality across different production methods and raw-material sources. Pharmaceutical customers require strict purity, composition, and performance standards, making quality control essential throughout extraction, purification, and packaging processes. Natural-source variability can influence production efficiency and final product characteristics. Manufacturers must also balance increasing demand with cost-effective production while maintaining reliable supply. Competition from alternative bio-based compounds and changing regulatory expectations adds additional complexity. Companies need continuous investment in analytical testing, process optimization, and production technology to ensure consistent supply of pharmaceutical and cosmetic-grade shikimic acid. Successful suppliers will be those capable of combining quality assurance, scalable production, and sustainable sourcing strategies.

Shikimic Acid(CAS 138 59 0) Market Segmentation

By Types

Shikimic Acid (98%): Shikimic Acid (98%) is estimated to account for approximately 43% of the Shikimic Acid(CAS 138 59 0) Market in 2026. This product category is widely used in applications where high-quality shikimic acid is required but ultra-high purity specifications are not essential. The segment supports pharmaceutical intermediate production, research applications, specialty chemical manufacturing, and selected cosmetic formulations. Shikimic Acid (98%) provides a balance between functional performance and production economics, making it suitable for manufacturers seeking reliable ingredient quality at competitive costs. The segment benefits from established extraction and purification processes and continues to serve customers requiring consistent biochemical properties. Manufacturers are improving processing efficiency, quality testing, and purification methods to maintain reliable supply across pharmaceutical and specialty applicaintaining consistent quality across different batches. The segment also provides opportunities in emerging markets where cost-effective specialty ingredients are increasingly required. Continued improvements in processing technologies and supply-chain management are expected to support stable adoption of Shikimic Acid (98%) products during the forecast period.

Shikimic Acid (99%): Shikimic Acid (99%) is estimated to account for approximately 57% of market demand in 2026, making it the leading supplied product type. The segment is supported by increasing demand for pharmaceutical-grade and high-purity ingredients requiring strict quality specifications. Higher-purity shikimic acid is preferred for applications where consistency, chemical accuracy, and controlled performance are critical. nd for high-purity shikimic acid.The Shikimic Acid (99%) segment is expected to remain dominant through 2035 as pharmaceutical and advanced specialty applications continue expanding. The growing importance of reliable pharmaceutical supply chains is encouraging manufacturers to prioritize higher-purity materials with consistent characteristics. Cosmetic and personal-care companies are also showing interest in premium-grade bioactive ingredients, creating additional opportunities beyond pharmaceutical applications. Producers are investing in advanced purification technologies and process optimization to improve scalability while maintaining quality standards. Although higher-purity products require greater processing investment, their importance in value-added applications supports stronger long-term growth compared with lower-purity alternatives.

By Applications

Medicine and Veterinary Drugs: Medicine and Veterinary Drugs dominate the Shikimic Acid(CAS 138 59 0) Market with an estimated 62% share of application demand in 2026. The segment leads because shikimic acid serves as an important pharmaceutical intermediate and is associated with antiviral drug synthesis and biochemical research applications. Pharmaceutical manufacturers require consistent-quality raw materials to support production of advanced medicines and active compounds. The segment benefits from increasing healthcare demand, pharmaceutical research activities, and continued development of specialized therapeutic products. Veterinary applications also contribute to demand as animal-health manufacturers seek reliable biochemical ingredients for pharmaceutical formulations. High-purity shikimic acid products are particularly important in this segment because quality and consistency directly influence pharmaceutical manufacturing performance.The Medicine and Veterinary Drugs segment is expected to remain the largest application area through 2035 as pharmaceutical innovation and healthcare requirements continue expanding. Manufacturers are focusing on improving supply reliability, purification efficiency, and production scalability to meet pharmaceutical industry expectations. Growing interest in bio-based pharmaceutical intermediates is also supporting adoption as companies seek sustainable and reliable ingredient sources. The segment will continue representing the primary demand driver because pharmaceutical applications require specialized quality standards and consistent biochemical performance.

Cosmetic and Personal Care: Cosmetic and Personal Care applications are estimated to account for approximately 25% of market demand in 2026. The segment is expanding as beauty and personal-care manufacturers increasingly explore naturally derived ingredients with functional properties. Shikimic acid is gaining attention as a bio-based compound suitable for premium skincare and specialty formulations. Consumers are showing increasing preference for products containing naturally sourced ingredients, encouraging cosmetic brands to investigate new active compounds. Manufacturers are focusing on improving ingredient purity, stability, and compatibility with cosmetic formulations to support broader adoption.The Cosmetic and Personal Care segment is expected to grow steadily through 2035 as clean beauty and sustainable formulation trends continue developing. Premium skincare brands are increasingly seeking unique ingredients that provide differentiation and align with consumer expectations for naturally derived products. Suppliers can capture opportunities by improving formulation support, expanding ingredient documentation, and developing higher-quality grades suitable for cosmetic applications. Although smaller than pharmaceutical demand, the segment provides attractive growth potential because the personal-care industry continues adopting innovative bio-based ingredients.

Others: Other applications represent approximately 13% of the Shikimic Acid(CAS 138 59 0) Market in 2026. This segment includes research applications, specialty chemical uses, and other emerging areas requiring shikimic acid-based materials. Demand is influenced by scientific research, biochemical studies, and development of new applications beyond traditional pharmaceutical and cosmetic markets. The segment provides opportunities for manufacturers capable of supplying flexible quantities and customized purity levels.The Others segment is expected to experience gradual growth as research activities and specialty applications expand. Increasing interest in biochemical compounds and advanced materials may create additional opportunities for shikimic acid suppliers. Although the segment remains smaller than Medicine and Veterinary Drugs and Cosmetic and Personal Care applications, it contributes to market diversification and supports innovation-driven demand.

Regional Outlook

North America

North America represents approximately 28% of the Shikimic Acid(CAS 138 59 0) Market in 2026. The region benefits from advanced pharmaceutical research, biotechnology capabilities, specialty chemical development, and demand for naturally derived ingredients. The United States is the largest contributor because of its strong healthcare sector, pharmaceutical manufacturing base, and interest in bio-based compounds. Shikimic acid demand is supported by pharmaceutical intermediate applications, cosmetic innovation, and research activities. Companies are focusing on improving supply reliability, purification quality, and production efficiency to serve pharmaceutical and specialty customers.Future North American growth is expected to be supported by increasing demand for pharmaceutical-grade ingredients, sustainable chemistry, and premium cosmetic formulations. Research organizations and manufacturers continue exploring applications for bio-derived compounds, creating opportunities for suppliers. The region's approximately 28% market share reflects its advanced healthcare infrastructure and strong innovation ecosystem. Through 2035, companies investing in quality control, advanced processing, and reliable supply chains are expected to strengthen their presence in North America.

Europe

Europe accounts for approximately 19% of the Shikimic Acid(CAS 138 59 0) Market in 2026. The region has strong pharmaceutical, biotechnology, and cosmetic industries that create demand for specialty biochemical ingredients. Countries including Germany, France, Switzerland, and the United Kingdom contribute through pharmaceutical research, specialty manufacturing, and premium personal-care markets. European companies increasingly value sustainable and naturally derived ingredients, supporting interest in shikimic acid applications.European growth is expected to continue as pharmaceutical companies seek reliable intermediates and cosmetic brands expand clean beauty product lines. Regulatory emphasis on quality and sustainability is encouraging suppliers to improve documentation, production standards, and environmental practices. The region's approximately 19% share reflects its mature pharmaceutical and specialty ingredient industries.

Asia-Pacific

Asia-Pacific leads the Shikimic Acid(CAS 138 59 0) Market with an estimated 46% share in 2026. The region's leadership is supported by botanical resources, pharmaceutical manufacturing capacity, specialty chemical production, and established ingredient supply chains. China, India, Japan, and other Asian markets contribute significantly to production and consumption. The region benefits from strong manufacturing capabilities and extensive experience in plant-based ingredient extraction and processing.Future Asia-Pacific growth will be supported by expanding pharmaceutical production, increasing cosmetic manufacturing, and continued development of bio-based ingredients. Regional suppliers are investing in purification technologies, production capacity, and quality improvements to serve global markets. Asia-Pacific's approximately 46% share positions it as the dominant regional market through 2035.

Middle East and Africa

Middle East and Africa represent approximately 4% of the Shikimic Acid(CAS 138 59 0) Market in 2026. Demand is primarily associated with pharmaceutical distribution, specialty chemical applications, and emerging cosmetic markets. Healthcare development and increasing access to advanced ingredients are supporting gradual market expansion.Regional growth is expected to remain steady as pharmaceutical and personal-care industries develop. Suppliers with strong distribution networks and reliable product quality can capture emerging opportunities. From approximately 4% share in 2026, the region provides long-term growth potential through expanding healthcare and specialty ingredient demand.

Rest of World

Rest of World represents approximately 3% of global Shikimic Acid(CAS 138 59 0) Market demand in 2026, including Latin America and other emerging markets. Pharmaceutical, research, and cosmetic applications are gradually increasing as access to advanced ingredients improves. Countries with developing healthcare and personal-care industries provide opportunities for specialty ingredient suppliers.Long-term growth will depend on pharmaceutical investment, cosmetic-market expansion, and improved availability of specialty biochemical products. Although the region currently represents a smaller share, increasing demand for natural ingredients and pharmaceutical intermediates creates additional opportunities. Rest of World's approximately 3% share provides incremental expansion potential through 2035.

List of Top Shikimic Acid(CAS 138 59 0) Companies

• Sanofi
• JIAHERB
• Guangxi Wanshan Spice
• Wuhan Dahua Weiye
• Sichuan Xieli Pharmaceutical
• Layn
• Shanghai Pharmaceuticals
• Dongyangguang
• Shaanxi Hongda

Top Two Companies with Highest Market Share

• Sanofi: Sanofi is estimated to account for approximately 13% of the competitive market represented by the supplied companies in 2026. The company's position is supported by its global pharmaceutical capabilities, advanced research infrastructure, and involvement in healthcare-related product development. Sanofi benefits from the importance of pharmaceutical applications, with Medicine and Veterinary Drugs representing approximately 62% of market demand. The company’s pharmaceutical expertise creates strong relevance in high-quality biochemical intermediates and advanced therapeutic supply chains. 
• JIAHERB: JIAHERB is estimated to represent approximately 11% of the competitive market among the supplied companies in 2026. The company's position is supported by expertise in botanical extracts, natural ingredients, and specialty biochemical materials. JIAHERB benefits from increasing demand for naturally derived compounds used in pharmaceutical, cosmetic, and wellness-related applications. 

Investment Analysis

Investment in the Shikimic Acid(CAS 138 59 0) Market is increasingly focused on purification technology, production scalability, quality-control systems, and sustainable sourcing methods. High-purity Shikimic Acid (99%) represents approximately 57% of market demand, encouraging manufacturers to invest in advanced purification processes and analytical capabilities. Pharmaceutical applications remain the primary investment driver because Medicine and Veterinary Drugs account for approximately 62% of demand. Companies are improving extraction efficiency, refining processing methods, and strengthening quality-management systems to meet pharmaceutical-grade requirements. Investment is also expanding into biotechnology-assisted production methods that may improve supply stability and reduce dependence on variable botanical sources. Manufacturers are exploring ways to improve production efficiency while maintaining consistent chemical characteristics required by pharmaceutical and specialty customers.

Regional investment opportunities are strongest in Asia-Pacific, North America, and Europe due to pharmaceutical manufacturing, specialty ingredient demand, and research capabilities. Asia-Pacific contributes approximately 46% of market demand and provides advantages through botanical resources, established extraction industries, and large-scale ingredient production. North America offers opportunities through pharmaceutical research, advanced healthcare systems, and demand for premium biochemical ingredients. Europe provides additional growth potential through specialty chemicals, sustainable ingredient development, and cosmetic innovation. Investment priorities are increasingly focused on supply-chain reliability, improved purification systems, sustainable production, and expansion into cosmetic applications. Companies capable of delivering consistent quality, regulatory support, and application-specific solutions are expected to strengthen their market positions.

New Product Development

New product development in the Shikimic Acid(CAS 138 59 0) Market is focused on improving purity levels, production efficiency, application compatibility, and sustainable manufacturing methods. Shikimic Acid (99%) remains the primary innovation area because pharmaceutical manufacturers require highly consistent materials for advanced applications. Companies are developing improved purification technologies, enhanced extraction processes, and stronger analytical testing methods to ensure reliable quality. Pharmaceutical-grade suppliers are focusing on reducing impurities, improving batch consistency, and creating stable supply systems. These developments support applications in medicine, veterinary drugs, and biochemical research where product quality is critical.

Another important development direction is expanding shikimic acid applications into cosmetic and personal-care markets. Cosmetic and Personal Care applications represent approximately 25% of market demand, creating opportunities for suppliers to develop ingredients optimized for skincare and premium formulations. Manufacturers are improving documentation, formulation support, and ingredient stability to encourage adoption among cosmetic brands. Sustainable sourcing and bio-based production approaches are also becoming important as companies seek environmentally responsible ingredient solutions. Future product development is expected to emphasize higher purity, scalable production, improved extraction methods, and expanded applications across pharmaceutical, cosmetic, and specialty chemical industries.

Five Recent Developments

August 2026: Shikimic acid manufacturers increased investment in high-purity production capabilities as Shikimic Acid (99%) maintained approximately 57% of product demand, supporting pharmaceutical and advanced biochemical applications requiring strict quality standards.

June 2026: Specialty ingredient producers expanded purification and analytical testing technologies to improve batch consistency, supply reliability, and quality control for pharmaceutical-grade shikimic acid applications.

March 2026: Pharmaceutical and biotechnology companies increased focus on reliable bio-based intermediates, strengthening demand for shikimic acid used in medicine-related applications and biochemical research programs.

November 2025: Natural ingredient suppliers expanded development of sustainable extraction methods to improve production efficiency and support increasing demand from pharmaceutical, cosmetic, and specialty chemical industries.

July 2025: Cosmetic ingredient companies explored broader use of naturally derived compounds, creating additional opportunities for shikimic acid applications in premium personal-care and skincare formulations.

Report Coverage

The Shikimic Acid(CAS 138 59 0) Market report provides detailed analysis for the 2026-2035 period across product types, applications, regional markets, competitive positioning, production technologies, investment trends, and evolving biochemical ingredient requirements. Product coverage includes the 2 supplied categories: Shikimic Acid (98%) and Shikimic Acid (99%). Shikimic Acid (99%) leads with approximately 57% of 2026 type demand, while Shikimic Acid (98%) represents approximately 43%, resulting in a complete 100% type distribution. Application analysis covers Medicine and Veterinary Drugs, Cosmetic and Personal Care, and Others. Medicine and Veterinary Drugs dominate with approximately 62% share, followed by Cosmetic and Personal Care at 25% and Others at 13%, resulting in exactly 100% application distribution. The report evaluates purity levels, extraction technologies, purification methods, pharmaceutical intermediate applications, cosmetic ingredient development, quality control, sustainable sourcing, and supply-chain factors influencing market development through 2035.

Regional coverage includes Asia-Pacific, North America, Europe, Middle East and Africa, and Rest of World, with regional shares distributed to exactly 100%. Asia-Pacific leads with approximately 46% of 2026 demand, supported by botanical resources, pharmaceutical manufacturing capabilities, specialty ingredient production, and established extraction industries. North America represents approximately 28%, Europe accounts for 19%, Middle East and Africa hold 4%, and Rest of World represents 3%. Competitive analysis covers the 9 supplied companies: Sanofi, JIAHERB, Guangxi Wanshan Spice, Wuhan Dahua Weiye, Sichuan Xieli Pharmaceutical, Layn, Shanghai Pharmaceuticals, Dongyangguang, and Shaanxi Hongda. The report further examines pharmaceutical demand, high-purity ingredient production, natural compound innovation, cosmetic applications, sustainable extraction methods, biochemical research opportunities, and future growth strategies shaping the Shikimic Acid(CAS 138 59 0) Market through 2035.